Over the last decade the combination of high unmet patient need and revenue potential has resulted in companies of all sizes moving into the Oncology space. Now competition is fierce and the pathway to success has many obstacles. There are more and more “‘me-too”, less clinically differentiated assets competing the same space with high prices. So, what is a pharma company to do when talking about the data is just not enough to win? In this podcast three ZS experts share insights on how to compete in this landscape.